- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
March 25, 2024 updated by: Loxo Oncology, Inc.
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This study includes 3 parts: Phase 1 (pirtobrutinib monotherapy dose escalation and dose expansion), Phase 1b (pirtobrutinib combination therapy dose expansion), and Phase 2 (pirtobrutinib monotherapy dose expansion).
In Phase 1, patients will be enrolled using an accelerated titration design.
The starting dose of pirtobrutinib in oral tablet form is 25 mg/day (e.g., 25 mg once daily [QD]).
Once the MTD and/or RP2D is identified in Phase 1 dose escalation, enrollment will continue to Phase 1 dose expansion and can commence to Phase 1b (Arms A and B).
For Phase 2, patients will be enrolled to one of seven Phase 2 dose expansion cohorts depending on tumor histology and prior treatment history.
Cycle length will be 28 days.
Study Type
Interventional
Enrollment (Estimated)
860
Phase
- Phase 2
- Phase 1
Expanded Access
Available outside the clinical trial.
See expanded access record.
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Patient Advocacy
- Phone Number: 1-855-569-6305
- Email: clinicaltrials@loxooncology.com
Study Locations
-
-
South Australia
-
Bedford Park, South Australia, Australia, 5042
- Flinders Medical Centre
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Peter MacCallum Cancer Centre
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Linear Clinical Research
-
-
-
-
-
Nantes Cedex 1, France, 44093
- Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
-
-
-
-
-
Bologna, Italy, 40138
- IRCCS - AOU di Bologna
-
Milano, Italy, 20132
- IRCCS Ospedale San Raffaele
-
-
-
-
-
Fukuoka, Japan, 811-1395
- National Hospital Organization Kyushu Cancer Center
-
Kyoto, Japan, 602-8566
- Kyoto Furitsu Medical University Hospital
-
Okayama, Japan, 700-8558
- Okayama University Hospital
-
Osakasayama-Shi, Japan, 589-8511
- Kindai University Hospital
-
-
Aichi
-
Nagoya, Aichi, Japan, 460-0001
- Nagoya Medical Center
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 060-8648
- Hokkaido University Hospital
-
-
Kanagawa
-
Isehara, Kanagawa, Japan, 259-1193
- Tokai University Hospital- Isehara Campus
-
-
Kochi
-
Nankoku, Kochi, Japan, 783-8505
- Kochi Medical School Hospital
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-8574
- Tohoku University Hospital
-
-
Tokyo
-
Chuo Ku, Tokyo, Japan, 104-0045
- National Cancer Center Hospital
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of, 06351
- Samsung Medical Center
-
-
-
-
-
Krakow, Poland, 30-510
- Pratia McM Kraków
-
Warszawa, Poland
- Instytut Hermatologii I Transfuzjologii
-
-
-
-
AB
-
Solna, AB, Sweden, 171 65
- Karolinska Institutet
-
-
-
-
Ticino
-
Bellinzona, Ticino, Switzerland, 6500
- Ospedale Regionale Bellinzona e Valli
-
-
-
-
-
Leeds, United Kingdom, LS9 7TF
- St James's University Hospital
-
Oxford, United Kingdom, OX3 7LJ
- Churchill Hospital
-
Plymouth, United Kingdom, PL6 8DH
- Derriford Hospital
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic of Scottsdale
-
-
California
-
San Diego, California, United States, 92103
- Scripps Coastal Medical Center
-
San Francisco, California, United States, 94117
- University of California San Francisco, Medical Center at Paranassus
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Smilow Cancer Hospital at Yale-New Haven
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic-Jacksonville
-
Lake Mary, Florida, United States, 32746
- Florida Cancer Specialists ORLANDO/DDU
-
Miami, Florida, United States, 33136
- Sylvester Comprehensive Cancer Center
-
Sarasota, Florida, United States, 34232
- Florida Cancer Specialists
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory Clinic
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905-0002
- Mayo Clinic
-
-
Nebraska
-
Omaha, Nebraska, United States, 68105
- University of Nebraska Medical Center
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
New Hyde Park, New York, United States, 11042
- Northwell Health
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
Durham, North Carolina, United States, 27705
- Durham VA Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, United States, 43210
- Ohio State University Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Hospital
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute SCRI
-
-
Texas
-
Dallas, Texas, United States, 75230
- Mary Crowley Cancer Research Center
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
- Utah Cancer Specialists
-
-
Washington
-
Seattle, Washington, United States, 98104
- Swedish Medical Center
-
Seattle, Washington, United States, 98195
- Seattle Cancer Care Alliance
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically confirmed CLL/SLL, WM, or NHL intolerant to either ≥ 2 prior standard of care regimens given in combination or sequentially OR have received 1 prior BTK inhibitor-containing regimen when a BTK inhibitor is approved as first line therapy (Phase 1) OR with prior treatment defined by phase 2 cohort (Phase 2 Patients only).
- Adequate hematologic function (Phase 1 and 1b Patients only).
- Responsive to transfusion support if given for thrombocytopenia or anemia (Phase 1 and 1b Patients only).
- Histologically confirmed relapsed/recurrent CLL in whom venetoclax is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm A Patients only).
- Histologically confirmed relapsed/refractory CLL in whom venetoclax + rituximab is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm B Patients only).
- Eastern Cooperative Oncology Group (ECOG) 0-2.
- Adequate hepatic and renal function.
- Ability to receive study drug therapy orally.
- Willingness of men and women of reproductive potential (defined as following menarche and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically sterile) to observe conventional and effective birth control.
Exclusion Criteria:
- Investigational agent or anticancer therapy within 5 half-lives or 14 days, whichever is shorter, prior to planned start of specified study therapy except antineoplastic and immunosuppressant monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of pirtobrutinib. In addition, no concurrent systemic anticancer therapy is permitted.
- Major surgery within 4 weeks prior to planned start of specified study therapy.
- Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment.
- Pregnancy or lactation.
- Patients requiring therapeutic anticoagulation with warfarin.
- Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 or greater at the time of starting study treatment except for alopecia.
- History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days (180 days before the PK trigger) prior to planned start of specified study therapy.
- Known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible and enrolled to phase 2 Cohort 7 if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.
- Active uncontrolled auto-immune cytopenia where new therapy introduced or concomitant therapy escalated within the 4 weeks prior to study enrollment is required to maintain adequate blood counts.
- Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of pirtobrutinib.
- Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.
- Patients who have tested positive for human immunodeficiency virus (HIV) are excluded. For patients with unknown HIV status, HIV testing will be performed at Screening and result should be negative for enrollment.
- Clinically significant active malabsorption syndrome.
- Current treatment with certain strong CYP3A4 inhibitors or inducers and/or strong P-gp inhibitors.
- For patients enrolled to phase 1b Arm A or B: Patients with prior treatment with venetoclax or other BCL-2 inhibitors.
- Prior treatment with pirtobrutinib.
- Active second malignancy unless in remission and with life expectancy > 2 years.
- Known hypersensitivity to any component or excipient of pirtobrutinib.
- For patients enrolled to phase 1b Arm B: Patients with prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation.
- Patients with prior significant hypersensitivity to rituximab requiring discontinuation, prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B Patients only).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase I Dose Escalation (Pirtobrutinib Monotherapy)
Dose Escalation and determination of MTD; multiple dose levels of pirtobrutinib to be evaluated
|
Oral
Other Names:
|
Experimental: Phase 2 (Pirtobrutinib Monotherapy) Cohort 3
CLL/SLL patients with no prior therapy.
|
Oral
Other Names:
|
Experimental: Phase 2 (Pirtobrutinib Monotherapy) Cohort 1
Non-blastoid MCL patients treated with a prior BTK-inhibitor containing regimen.
|
Oral
Other Names:
|
Experimental: Phase 2 (Pirtobrutinib Monotherapy) Cohort 4
CLL/SLL patients treated with prior therapy, BTK inhibitor naïve.
|
Oral
Other Names:
|
Experimental: Phase 2 (Pirtobrutinib Monotherapy) Cohort 2
CLL/SLL patients treated with 2 or more prior regimens, including a BTK inhibitor-containing regimen.
|
Oral
Other Names:
|
Experimental: Phase 2 (Pirtobrutinib Monotherapy) Cohort 5
WM patients treated with a prior BTK inhibitor-containing regimen.
|
Oral
Other Names:
|
Experimental: Phase 2 (Pirtobrutinib Monotherapy) Cohort 6
MZL patients treated with a prior BTK inhibitor-containing regimen.
|
Oral
Other Names:
|
Experimental: Phase 2 (Pirtobrutinib Monotherapy) Cohort 7
Defined as CLL/SLL or NHL not otherwise specified in Cohorts 1 through 6, inclusive of CLL/SLL, Richter's transformation, or low grade NHL with transformation, blastoid MCL, and patients with history of CNS involvement or primary CNS lymphoma.
In the event the Sponsor electively closes Cohorts 2-4 prior to completion, patients with CLL/SLL who are ineligible to participate in or unable to access late phase studies of pirtobrutinib may be eligible to enroll in this cohort Diffuse large B-cell lymphoma (DLBCL) is excluded.
MCL without prior BTK inhibitor treatment is excluded.
Patients enrolling to Cohort 7 must have received one or more prior therapies or have no available approved therapy with demonstrated clinical benefit with the exception of untreated Richter's transformation, which is allowed.
|
Oral
Other Names:
|
Experimental: Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm A
Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax
|
Oral
Other Names:
Oral
Other Names:
|
Experimental: Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm B
Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax and rituximab
|
IV
Other Names:
Oral
Other Names:
Oral
Other Names:
|
Experimental: Phase 1 Dose Expansion (Pirtobrutinib Monotherapy)
Patients to receive the recommended Phase 2 dose of pirtobrutinib
|
Oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD)
Time Frame: Up to 24 Months
|
Phase I
|
Up to 24 Months
|
Recommended dose for further study
Time Frame: Up to 24 Months
|
Phase I
|
Up to 24 Months
|
To assess the preliminary anti-tumor activity of pirtobrutinib based on ORR as assessed by an Independent Review Committee (IRC).
Time Frame: Up to 24 months
|
Phase II
|
Up to 24 months
|
To evaluate the safety of pirtobrutinib in combination with venetoclax (Arm A) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0
Time Frame: Up to 24 Months
|
For Phase 1b
|
Up to 24 Months
|
To evaluate the safety of pirtobrutinib in combination with venetoclax and rituximab (Arm B) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0
Time Frame: Up to 24 Months
|
For Phase 1b
|
Up to 24 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the safety profile and tolerability of pirtobrutinib including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events.
Time Frame: Up to 24 Months
|
Phase I
|
Up to 24 Months
|
To characterize the pharmacokinetics (PK) properties of pirtobrutinib by collecting and evaluating serum at protocol specified time points.
Time Frame: Up to 24 Months
|
Phase I
|
Up to 24 Months
|
To assess the preliminary anti-tumor activity of pirtobrutinib based on overall response rate (ORR) as assessed by investigator.
Time Frame: Up to 24 Months
|
Phase I
|
Up to 24 Months
|
ORR as assessed by the Investigator.
Time Frame: Up to 24 Months
|
Phase II
|
Up to 24 Months
|
Best overall response (BOR) as assessed by the Investigator and IRC.
Time Frame: Up to 24 Months
|
Phase II
|
Up to 24 Months
|
Duration of response (DOR) as assessed by the Investigator and IRC.
Time Frame: Up to 24 Months
|
Phase II
|
Up to 24 Months
|
Progression free survival (PFS) as assessed by the Investigator and IRC.
Time Frame: Up to 24 Months
|
Phase II
|
Up to 24 Months
|
Overall survival (OS).
Time Frame: Up to 24 Months
|
Phase II
|
Up to 24 Months
|
To determine the safety profile and tolerability of pirtobrutinib including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events
Time Frame: Up to 24 Months
|
Phase II
|
Up to 24 Months
|
To characterize the pharmacokinetics (PK) properties of pirtobrutinib by collecting and evaluating serum at protocol specified time points.
Time Frame: Up to 24 Months
|
Phase II
|
Up to 24 Months
|
To characterize the pharmacokinetics (PK) properties of pirtobrutinib by collecting and evaluating serum at protocol specified time points.
Time Frame: Up to 24 months
|
For Phase 1b
|
Up to 24 months
|
To assess the preliminary anti-tumor activity of pirtobrutinib in combination based on overall response rate (ORR) as assessed by investigator.
Time Frame: Up to 24 months
|
For Phase 1b
|
Up to 24 months
|
Symptomatic Response: Change from Baseline in Mantle Cell Lymphoma (MCL)-related symptoms selected from the European Organisation for Research and Treatment of Cancer (EORTC) Item Library
Time Frame: Baseline, End of Treatment (Estimated Up to 24 Months)
|
Individual EORTC symptom scores range from 1 (not at all) to 4 (very much) with higher scores representing more severe symptom severity.
|
Baseline, End of Treatment (Estimated Up to 24 Months)
|
Functional Response: Change from Baseline in Physical Functioning as Measured by Physical Functioning Scale from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0 (EORTC QLQ)
Time Frame: Baseline, End of Treatment (Estimated Up to 24 Months)
|
EORTC physical function item scores range from 1 (not at all) to 4 (very much) with higher scores indicating poorer functioning.The total EORTC physical functioning score ranges from 0-100 where a higher score indicates higher/healthier level of functioning.
|
Baseline, End of Treatment (Estimated Up to 24 Months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Donald Tsai, MD, PhD, Loxo Oncology
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Kipps TJ. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01;27(4):306-313. doi: 10.1097/PPO.0000000000000536.
- Cohen JB, Shah NN, Alencar AJ, Gerson JN, Patel MR, Fakhri B, Jurczak W, Tan XN, Lewis KL, Fenske T, Coombs CC, Flinn IW, Lewis DJ, Gouill SL, Palomba ML, Woyach JA, Pagel JM, Lamanna N, Barve MA, Ghia P, Eyre TA, Zinzani PL, Ujjani CS, Koh Y, Izutsu K, Lech-Maranda E, Tam CS, Sundaram S, Yin M, Nair B, Tsai DE, Balbas M, Mato AR, Cheah CY, Wang ML. MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S394-S395. doi: 10.1016/S2152-2650(22)01569-5.
- Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, Gagea M, Bertilaccio MTS, Wierda WG, Gandhi V. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 2022 May 20;12(5):80. doi: 10.1038/s41408-022-00675-9.
- Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 Mar 6;397(10277):892-901. doi: 10.1016/S0140-6736(21)00224-5.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 16, 2018
Primary Completion (Estimated)
September 1, 2027
Study Completion (Estimated)
January 1, 2028
Study Registration Dates
First Submitted
November 6, 2018
First Submitted That Met QC Criteria
November 12, 2018
First Posted (Actual)
November 14, 2018
Study Record Updates
Last Update Posted (Actual)
March 26, 2024
Last Update Submitted That Met QC Criteria
March 25, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
- Rituximab
- NHL
- Follicular Lymphoma
- Ibrutinib
- Venetoclax
- CLL
- Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Waldenstrom macroglobulinemia
- Mantle Cell Lymphoma
- SLL
- BTK
- C481S
- BCL2
- Acalabrutinib
- Zanubrutinib
- LOXO-305
- Marginal zone lymphoma
- Small Lymphocytic Lymphoma
- BGB-3111
- Loxo
- Primary CNS Lymphoma
- Bruton's tyrosine kinase
- Richter's Transformation
- C481
- GS-4059
- ONO-4059
- Tirabrutinib
- BTK Intolerant
- C481S Mutation
- DLBCL (Diffuse Large B-cell lymphoma)
- PI3KD
- Idelalisib
- Umbralisib
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Disease Attributes
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Leukemia, B-Cell
- Chronic Disease
- Lymphoma
- Lymphoma, B-Cell
- Leukemia
- Lymphoma, Mantle-Cell
- Lymphoma, B-Cell, Marginal Zone
- Waldenstrom Macroglobulinemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Venetoclax
- Rituximab
- Pirtobrutinib
Other Study ID Numbers
- LOXO-BTK-18001 (BRUIN)
- 2018-003340-24 (EudraCT Number)
- J2N-OX-JZNA (Other Identifier: Eli Lilly and Company)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on B-cell Lymphoma
-
Iksuda Therapeutics Ltd.RecruitingFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin LymphomaAustralia, Canada, United States
-
Nathan DenlingerBristol-Myers SquibbRecruitingB-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditionsUnited States
-
AstraZenecaRecruitingFollicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin LymphomaKorea, Republic of, United States, Japan, Australia, Taiwan
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Massachusetts General HospitalVarian Medical SystemsRecruitingLymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell LymphomaUnited States
-
University of ChicagoMerck Sharp & Dohme LLCRecruitingLymphoma | Lymphoma, B-Cell | B Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell LymphomaUnited States
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
University of NebraskaBristol-Myers SquibbRecruitingFollicular Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma | Mediastinal Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
Curocell Inc.RecruitingHigh-grade B-cell Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Transformed Follicular Lymphoma (TFL) | Refractory Large B-cell Lymphoma | Relapsed Large B-cell LymphomaKorea, Republic of
Clinical Trials on Rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
PfizerCompletedRheumatoid ArthritisUnited States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
-
Mabion SAParexelWithdrawn
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States